Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund - Direct Plan - Growth Plan

Add To Compare

previously known as Reliance Pharma Dir Gr until

NAV on March 23, 2023
Category Equity:
Sector - Healthcare
Investment StyleBox
Large Growth
Total Assets 4,268 cr
Turnover Ratio 38.42%
Expense Ratio 1.26%
Exit Load 1.00%if redeemed within
1 Months
0.00%if redeemed after 1 Months
Returns
  • 1M: -0.76%
  • 1Y: -6.13%
  • 3M: -6.05%
  • 3Y: 28.27%
  • 6M: -2.11%
  • 5Y: 16.20%
Min Investment 5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since almost 18 years) Kinjal Desai (Since almost 5 years) Akshay Sharma (Since 4 months)
ISIN INF204K01I50
Fund Family Nippon India
P/E Ratio 31.38
P/B Ratio 3.88
Launch Date January 01, 2013
Benchmark S&P BSE Healthcare TR INR
ASSET ALLOCATION
EQUITY DISTRIBUTION
RISK MEASURES (3 yrs)
vs S&P BSE Healthcare TR INR

Alpha 3.17
Beta 0.94
R-Squared 97.59
Info Ratio 0.82
Tracking Err 3.59
Sortino 1.715
Sharpe 0.785
Std Dev 21.377
Risk -
SECTOR WEIGHTINGS (%)
Financial 0.0%
Industrial 0.0%
Technology 0.0%
Basic Materials 0.0%
Consumer Cyclical 0.0%
Utilities Services 0.0%
Healthcare Services 100.00%
Energy Services 0.00%
Communication Services 0.00%
Consumer Defensive 0.00%
Real Estate 0.00%
INVESTMENT OBJECTIVE

The Fund seeks to invest in pharma sector with focus on important segments of the sector viz Domestic Business, International & CRAMS and include deep value as well as high growth pharma businesses. The fund invests across market capitalization within the sector. It may suit investment horizon of around 2-3 years.

You will not receive any dividends. Your investments will get the largest benefit of compounding.

View Factsheet

-
Best Sector Healthcare Funds
NAME LATEST
NAV
RETURNS
1y    
FUND
ASSETS
Expense
RATIO
RISK
240.197 -0.89% 1,632 cr 1.09% -


Other plans of Nippon India Pharma


Other Equity funds by Nippon India